# PROCEPT BioRobotics Corp

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/PROCEPT BioRobotics Corp).

## Overview

PROCEPT BioRobotics Corp develops and commercializes robotic systems for urology procedures, centered on Aquablation therapy for benign prostatic hyperplasia (BPH). The company sells its systems, single-use handpieces, accessories, and related service offerings primarily in the United States, with additional commercial activity in international markets through direct sales and distributors.

## Products & services

• AquaBeam Robotic System
• HYDROS Robotic System
• Single-use disposable handpieces
• Accessories and probes
• Service, repair, and extended service contracts
• Sales-type leasing arrangements

- **Robotic systems** (45%) — Capital equipment used to deliver Aquablation therapy in urology procedures.
- **Single-use handpieces** (35%) — Disposable handpieces used during each Aquablation procedure.
- **Accessories and probes** (8%) — Ancillary components shipped with or used alongside the robotic systems.
- **Service and repair** (7%) — Maintenance, repair, and support services for installed systems.
- **Leasing and other revenue** (5%) — Sales-type leasing arrangements and other related commercial revenue.

- AquaBeam Robotic System
- HYDROS Robotic System
- Single-use disposable handpieces
- Accessories and probes
- Service, repair, and extended service contracts
- Sales-type leasing arrangements

## Customers

The company sells primarily to hospitals in the United States, where the end users are urologists and surgical teams performing BPH procedures. Outside the U.S., it works through direct sales teams and distribution partners, with market access shaped by reimbursement, surgeon training, and regulatory approval pathways.

- **Hospitals** (primary) — Primary buyers of robotic systems and disposables for hospital-based BPH procedures.
- **Urologists and surgeons** (primary) — Clinical decision-makers who evaluate outcomes, usability, and evidence before adoption.
- **Ambulatory surgery centers** (secondary) — Purchase or access systems for outpatient BPH treatment in selected settings.
- **Distribution partners** (secondary) — Support sales, training, and market development outside the United States.
- **Leasing customers** (secondary) — Access the systems through sales-type leasing rather than outright purchase.

- Hospitals purchasing systems for BPH procedures
- Urologists and surgeons who drive adoption and utilization
- Ambulatory surgery centers in selected markets
- Leasing companies that finance system access
- Distribution partners supporting international market entry

## Geography

The United States is the company’s core market and accounted for 88% of revenue in 2025, with 12% from outside the United States. Manufacturing is centered in San Jose, California, while logistics and shipping rely on third-party providers in the United States, United Kingdom, and the Netherlands to serve global customers.

- **United States** (88%)
- **Outside the United States** (12%)

- United States generated 88% of 2025 revenue
- Outside the United States generated 12% of 2025 revenue
- Manufacturing is based in San Jose, California
- Third-party logistics support shipments from the U.S., U.K., and Netherlands
- International growth depends on reimbursement and distributor coverage

## Strategy

The company’s strategy is to expand the installed base of robotic systems, increase procedure utilization, and grow recurring handpiece sales tied to each surgery. It also invests in next-generation product development, software, and AI-enabled planning tools to improve Aquablation therapy and strengthen its competitive position.

- **Expand the installed base of robotic systems** (short-term) — More installed systems create future recurring handpiece and service revenue.
- **Improve manufacturing scale and efficiency** (medium-term) — Higher production volumes can reduce per-unit costs and support margins.
- **Advance next-generation product and software development** (medium-term) — Product improvements help sustain differentiation versus surgical and non-surgical alternatives.
- **Expand reimbursement and market access** (short-term) — Coverage and payment determine whether hospitals and physicians adopt the therapy.

- Expand installed base of robotic systems
- Increase procedure volume and handpiece utilization
- Improve manufacturing scale and unit economics
- Develop next-generation Aquablation technologies
- Add software and AI for anatomy recognition and planning
- Broaden reimbursement and market access

## Risks

The business depends on clinical adoption, reimbursement coverage, and continued regulatory compliance for a medical device platform used in surgery. It also faces manufacturing, supplier, and product-safety risks because the systems rely on regulated components, single-source suppliers, and post-market surveillance.

- **Reimbursement and coverage risk** [high] — Hospitals and physicians may not adopt Aquablation if payers do not cover the procedure adequately.
- **Product safety and recall risk** [high] — Adverse events, malfunctions, or manufacturing defects can trigger recalls, reporting obligations, or market restrictions.
- **Supplier concentration risk** [high] — Many components are sourced from single-source suppliers, so disruptions can affect production and delivery.
- **Competitive pressure** [medium] — The company competes against established surgical and non-surgical BPH treatments with broader brand recognition and reimbursement coverage.
- **Regulatory compliance risk** [high] — Failure to meet FDA and other device regulations can lead to delays, sanctions, or loss of approvals.

- Adoption depends on reimbursement and payer coverage
- Medical device recalls or adverse events could disrupt sales
- Single-source suppliers create supply-chain concentration risk
- Competition from TURP, laser, and non-surgical BPH therapies is intense
- Regulatory compliance failures could delay shipments or approvals

## Accounting

Revenue recognition is driven by a mix of system sales, sales-type leases, disposable handpieces, accessories, and service contracts, so timing depends on contract terms and delivery. Investors should also watch geographic mix, because U.S. sales carry different pricing and margin characteristics than international sales, and quarterly results can move with system placements and procedure volumes.

- **Revenue recognition across multiple product and service streams** — Systems, handpieces, leases, and service contracts
- **Sales-type lease accounting** — Capital equipment sales channel
- **Warranty and post-market obligations** — Robotic systems and handpieces
- **Geographic mix and quarterly seasonality** — Revenue and gross margin
- **Inventory and supply-chain estimates** — Cost of sales and inventory valuation

- Revenue comes from systems, disposables, accessories, and service contracts
- Sales-type leases affect timing and presentation of revenue
- Geographic mix influences reported revenue and gross margin
- Warranty, repair, and post-market obligations require estimates
- Inventory and supplier issues can affect cost of sales and reserves

---

*Last updated: 2026-04-29T04:46:55.177024+00:00*